VISINE A OTC
Generic Name and Formulations:
Naphazoline HCl 0.025%, pheniramine maleate 0.3%; oph soln; contains benzalkonium chloride.
McNeil Consumer Healthcare
Indications for VISINE A:
Temporary relief of ocular redness and itching.
Adults and Children:
<6yrs: not recommended. ≥6yrs: 1–2 drops up to 4 times daily.
Avoid prolonged use. Narrow-angle glaucoma. Hypertension. Cardiovascular disease. Urinary hesitancy. Reevaluate if eye pain, irritation, or visual changes worsen or persist beyond 72hrs. Pregnancy. Nursing mothers.
Vasoconstrictor + antihistamine.
Avoid MAOIs. Remove soft contact lenses when instilling; may re-insert afterwards.
Mydriasis, increased IOP, local irritation, sensitization.
Neurology Advisor Articles
- Excess Abdominal Obesity Linked to Severe Disability in Multiple Sclerosis
- Change in Dietary Patterns Over 5 Years in Early Multiple Sclerosis
- High-Dose Biotin May Be an Effective Treatment for Progressive MS
- Biobank Data Suggest Vitamin D Reduces Risk for Multiple Sclerosis
- Poor Functional Outcomes Tied to Depressive Symptoms in Multiple Sclerosis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Oxygen Desaturation Index Predicts AFib Risk in Ischemic Stroke
- Opioid Use Down With 'Enhanced Recovery After Surgery' Program
- Popular Heroin Inhalation Method Tied to Leukoencephalopathy
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL